John A. Allen

Military Health Care

Rr612 Everrett Creek Road
Camp Lejeune, NC 28542

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12.

Discovery of Small Molecule Ligands Targeting Orphan G Protein-Coupled Receptors GPR3, GPR6, and GPR12.

Journal: Journal of medicinal chemistry

Published: June 18, 2026

CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease.

CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease.

Journal: Journal of medicinal chemistry

Published: April 09, 2026

Probing chemical space and conformational changes for subtype-selective orexin receptor antagonists.

Probing chemical space and conformational changes for subtype-selective orexin receptor antagonists.

Journal: RSC medicinal chemistry

Published: February 12, 2026

Constitutive activity among orphan G protein-coupled receptors: Molecular mechanisms and pharmacological perspectives.

Constitutive activity among orphan G protein-coupled receptors: Molecular mechanisms and pharmacological perspectives.

Journal: Molecular pharmacology

Published: September 15, 2025

Functionally Selective Dopamine D1 Receptor Endocytosis and Signaling by Catechol and Noncatechol Agonists.

Functionally Selective Dopamine D1 Receptor Endocytosis and Signaling by Catechol and Noncatechol Agonists.

Journal: Biochemistry

Published: March 20, 2025

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists.

Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists.

Journal: Journal of medicinal chemistry

Published: May 24, 2024

Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists.

Functionally selective dopamine D1 receptor endocytosis and signaling by catechol and non-catechol agonists.

Journal: bioRxiv : the preprint server for biology

Published: April 25, 2024

Orphan GPR52 as an emerging neurotherapeutic target.

Orphan GPR52 as an emerging neurotherapeutic target.

Journal: Drug discovery today

Published: December 12, 2023

Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target.

Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target.

Journal: ACS chemical neuroscience

Published: September 07, 2023

Retraction of "Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists".

Retraction of "Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists".

Journal: ACS medicinal chemistry letters

Published: June 16, 2022

Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior.

Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior.

Journal: Journal of medicinal chemistry

Published: November 17, 2020

High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na+ channel complex.

High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na+ channel complex.

Journal: Scientific reports

Published: June 13, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026